Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2026 Aug 16.
Published before final editing as: Ophthalmology. 2026 Jul 30:S0161-6420(26)00531-2. doi: 10.1016/j.ophtha.2026.07.027

Factors Associated with Endothelial Cell Density at One Year in the Diabetes Endothelial Keratoplasty Study

Sanjay V Patel 1, Beth Ann Benetz 2,3, Marianne O Price 4, Zachariah W Reed 5, Robin L Gal 5, Loretta B Szczotka-Flynn 2, Brandon D Ayres 6, Michelle Boyce 7, Christopher R Croasdale 8, M Bowes Hamill 9, Mark S Hansen 10, Ahmed F Omar 2,11, Luke B Potts 12, Jesse M Vislisel 13, Roy W Beck 5, Jonathan H Lass 2,3, on behalf of the Diabetes Endothelial Keratoplasty Study Group
PMCID: PMC13476862  NIHMSID: NIHMS2201152  PMID: 42532315

Abstract

Objective:

To evaluate donor, recipient, and operative factors associated with endothelial cell density (ECD) at 1 year after Descemet membrane endothelial keratoplasty (DMEK) in the Diabetes Endothelial Keratoplasty Study (DEKS).

Design:

This prospective cohort study was a pre-defined secondary analysis of the DEKS multicenter, double-masked, randomized clinical trial.

Participants:

Subjects undergoing DMEK without graft failure and with analyzable endothelial images at 1 year.

Methods:

A central, masked image analysis reading center determined ECD from central endothelial images of corneal grafts from donors without or with diabetes preoperatively and 1 year after DMEK. Associations between ECD at 1 year and donor, recipient, and operative factors were assessed using multivariable linear mixed-effect models adjusting for surgeon (random effect) and accounting for correlation between fellow donor and recipient eyes.

Main outcome measure:

Post-DMEK ECD at 1 year.

Results:

Of 1421 eyes undergoing DMEK, 1274 eyes were included in this analysis; 724 (57%) were in women, 1215 (95%) were in white individuals, and 1229 (96%) had Fuchs endothelial corneal dystrophy (FECD). Lower ECD (estimated effect [99% CI]) at 1 year was associated with lower donor preoperative ECD (−392 [−447 to −336] cells/mm2 per 500 cells/mm2 preoperatively), eye bank-reported donor endothelial cell damage (−161 [−281 to −40] cells/mm2) for 10–20% cell damage by trypan blue staining post lenticule preparation vs. <5% damage, operative complications (−308 [−450 to −166] cells/mm2), and recipient indication other than FECD (−191 [−346 to −36] cells/mm2). One-year endothelial cell loss from preoperative was 26% to 30% across preoperative ECD groups (<2500, 2500 to <2750, 2750 to <3000, ≥3000 cells/mm2), was 36% when there was 10–20% endothelial cell damage after lenticule preparation vs. 29% for <5% cell damage, was 28% when the preoperative indication was FECD vs. 40% when it was not, and was 42% when intraoperative complications occurred vs. 27% when they did not.

Conclusions:

Higher endothelial cell loss at 1 year after DMEK is associated with endothelial cell damage following lenticule preparation, recipient indication other than FECD, and intraoperative complications. Estimating donor endothelial cell damage by trypan blue staining was an independent assessment of donor endothelial health that complemented ECD.

Keywords: Descemet membrane endothelial keratoplasty, endothelial cell density, endothelial cell loss, corneal endothelium

Précis

In a pre-defined secondary analysis of the Diabetes Endothelial Keratoplasty Study, modifiable risk factors for higher endothelial cell loss at 1 year after DMEK were intraoperative complications and donor endothelial cell damage following lenticule preparation.

Introduction

Endothelial cell loss (ECL) at 6 months after Descemet stripping automated endothelial keratoplasty (DSAEK) was associated with subsequent late endothelial graft failure in the Cornea Preservation Time Study (CPTS),1 indicating the importance of understanding, and potentially mitigating, risk factors for ECL. Risk factors for ECL after DSAEK2 were different from those after penetrating keratoplasty (PK),3–5 reflecting differences in donor tissue preparation and surgical manipulation of the graft between these procedures. With further variation in how donor tissue is handled for Descemet membrane endothelial keratoplasty (DMEK), understanding the risk factors for ECL after DMEK could help optimize DMEK graft survival.

The Diabetes Endothelial Keratoplasty Study (DEKS) was a large, multicenter, prospective, randomized trial that investigated the effect of diabetes in the donor on DMEK graft survival and ECL.6 The study found that diabetes in the donor did not affect graft survival or ECL at 1 year after DMEK.7,8 The purpose of the present pre-defined secondary analysis of the DEKS was to investigate donor, donor tissue, recipient, and operative factors associated with ECL after DMEK by determining changes in endothelial cell density (ECD) from before to after DMEK. This analysis complements a recent study of risk factors for graft success in the DEKS.9

Methods

The detailed methods for the DEKS and the primary outcome results have been published previously.6–8 Eyes undergoing DMEK were randomized to receive donor tissue from subjects without or with diabetes, as defined by donor hemoglobin A1c level (≥6.5% indicated diabetes was present).6 The DEKS was a National Eye Institute-funded multicenter clinical trial, was approved by the Jaeb Center for Health Research Institutional Review Board, and adhered to the tenets of the Declaration of Helsinki. Written informed consent was obtained from all participants. The study was registered as a clinical trial at ClinicalTrials.gov (NCT05134480).

All recipients had corneal endothelial dysfunction and were enrolled between February 2022 and July 2024. Exclusion criteria included high-risk recipient eyes, e.g. those with PK failure or glaucoma drainage devices.6 Donor corneas had a minimum endothelial cell density (ECD) of 2300 cells/mm2 as determined by eye bank measurements. Multiple donor, donor tissue, recipient, and operative factors were collected prospectively and analyzed with respect to ECD at 1 year after DMEK.

Endothelial Cell Imaging and Analysis

Endothelial cell image analysis followed well established protocols for image acquisition (including image quality and calibration) and analysis, and was overseen by the Corneal Image Analysis Reading Center (CIARC) at Case Western Reserve University and University Hospitals Eye Institute (Cleveland, OH).6,8,10 Eye banks provided 1 to 3 endothelial images for preoperative ECD measurement by the CIARC. At 1 and 12 months after DMEK, clinical sites submitted 3 postoperative endothelial images to the CIARC for analysis. Endothelial images were analyzed by using the “center” method11,12 (Konan Medical, Irvine, CA) to derive endothelial cell morphometry (i.e., coefficient of variation of cell size and % of hexagonal cells) in addition to ECD.8 Because we previously found little change in morphometry that was unrelated to donor diabetes or diabetes severity at 1 year in the DEKS,8 the present analysis was confined to factors associated with ECD.

Endothelial Cell Damage

Endothelial cell damage was assessed after DMEK lenticule preparation had been completed and prior to loading by staining donor corneas with trypan blue 0.06% for 30 seconds followed by rinsing with balanced salt solution.13 Trained eye bank technicians and surgeons preparing their own tissue assessed the percentage of stained areas relative to the intended graft area. Training was required and included strategies for the visual assessment and comparisons between visual and automated assessments of the same images (automated image processing for segmentation and quantification of the stained area). Technicians and surgeons preparing their own tissue were examined to be within 5% accuracy of objective assessment of the same images using image analysis software and to correctly identify grafts with >20% cell damage, which were disqualified for the DEKS.6

Statistical Analysis

Only eyes without graft failure and with at least one analyzable endothelial image preoperatively and at 1 year after DMEK were included for analysis.8 Mean and standard deviation of ECD were tabulated by each factor level at screening, 1 month, and 1 year. Summary statistics for ECL, which was the change in ECD after DMEK compared to donor preoperative ECD (%), were tabulated at 1 month and 1 year, and the association between ECL at 1 month and 1 year was assessed by the Pearson correlation coefficient. Longitudinal linear mixed-effects models were used to evaluate associations between candidate factors and ECD over time. Each model included ECD as the outcome and adjusted for screening ECD, donor diabetes status, and recipient diagnosis as fixed effects, with surgeon, recipient, and donor included as random effects. Statistical significance was defined as α = 0.01. Initially, each factor was evaluated in a separate model. Factors meeting the significance threshold were then included together in a multivariable model with ECD as the outcome, and adjusted P-values and 99% confidence Intervals (CIs) were reported. Continuous covariates were modeled continuously but categorized for presentation in tables to aid interpretation.

Results

Of 1421 eyes undergoing DMEK in the DEKS, 1274 eyes included in this analysis had ≥1 analyzable postoperative endothelial image at either 1 month or 1 year and were without graft failure at 1 year.8 At 1 year, 1103 eyes had analyzable endothelial images and were without graft failure.8 Of the 1274 eyes included for analysis, 724 (57%) were in women, 1215 (95%) were in white individuals, and 1229 (96%) had Fuchs endothelial corneal dystrophy (FECD).

Endothelial cell density before DMEK and at 1 month and 1 year after DMEK is shown for each donor, donor tissue, recipient, and operative factor (Tables 1–4). There was an association between ECL at 1 month and 1 year (r=0.83, P<0.001). Independent risk factors for lower ECD at 1 year in the final multivariable model are shown in Table 5. Lower preoperative donor ECD by 500 cells/mm2 was associated with a lower ECD (estimated effect [99% CI]) at 1 year by 392 [336 to 447] cells/mm2 (P<0.001). Eye bank-reported endothelial cell damage by trypan blue staining after lenticule preparation was associated with lower ECD at 1 year after DMEK (−161 [−281 to −40] cells/mm2 lower when there was 10–20% endothelial cell damage compared to <5% endothelial cell damage, P<0.001). Lower ECD at 1 year was also associated with intraoperative complications (lower by 308 [−450 to −166] cells/mm2, P<0.001) and any preoperative indication other than Fuchs dystrophy (lower by 191 [−346 to −36] cells/mm2, P=0.001). There were no associations between ECD at 1 year and numerous other factors (Tables 1–4), including donor age, donor diabetes status, timing of lenticule preparation, graft diameter, preoperative and postoperative lens status, anterior chamber air/gas volume, complete air/gas fill duration, trainee participation, or whether surgery was performed at a private or academic site.

Table 1.

Donor Factors Affecting ECD at 1 Year

Screening 1 Month 1 Year
Risk Factor N ECD
Mean ± SD
N ECD
Mean ± SD
% ECL
Mean ± SD
N ECD
Mean ± SD
% ECL
Mean ± SD
P-Value1
Overall 1274 2674 ± 289 1164 2039 ± 458 23.6 ± 15.2 1103 1925 ± 497 28.2 ± 16.4
Age2 0.83
 50 to 64 618 2682 ± 288 567 2032 ± 464 24.1 ± 15.4 534 1926 ± 505 28.4 ± 16.6
 65 to 75 656 2667 ± 290 597 2046 ± 453 23.1 ± 15.1 569 1924 ± 490 28.0 ± 16.3
Sex 0.03
 Female 529 2642 ± 277 478 1987 ± 460 24.7 ± 15.7 458 1892 ± 505 28.6 ± 17.1
 Male 745 2697 ± 295 686 2076 ± 454 22.9 ± 14.8 645 1948 ± 491 27.9 ± 15.9
Race/ethnicity (N=1068)3 0.04
 Non-Hispanic White 960 2668 ± 290 873 2003 ± 467 24.8 ± 15.6 830 1886 ± 497 29.4 ± 16.5
 Other4 108 2775 ± 281 100 2124 ± 416 23.2 ± 13.7 89 2036 ± 471 26.7 ± 15.4
Diabetes status 0.62
 Without diabetes 816 2676 ± 290 745 2045 ± 461 23.5 ± 15.0 710 1927 ± 498 28.3 ± 16.1
 With diabetes 458 2671 ± 286 419 2030 ± 453 23.8 ± 15.6 393 1920 ± 496 28.0 ± 17.0
Pre-Operative CIARC-measured ECD2,5 <0.001
 <2500 399 2355 ± 110 368 1798 ± 393 23.7 ± 16.3 340 1651 ± 415 29.9 ± 17.1
 2500–<2750 389 2626 ± 70 358 2017 ± 389 23.1 ± 14.8 342 1891 ± 427 28.0 ± 16.3
 2750–<3000 308 2870 ± 72 278 2180 ± 430 24.0 ± 14.9 268 2114 ± 440 26.4 ± 15.2
 ≥3000 178 3156 ± 135 160 2400 ± 465 23.9 ± 14.3 153 2277 ± 549 28.0 ± 17.0
Severity of donor folds 0.51
 None/mild 1124 2676 ± 290 1024 2038 ± 461 23.7 ± 15.3 968 1925 ± 502 28.2 ± 16.6
 Moderate/severe 150 2664 ± 281 140 2050 ± 442 22.9 ± 14.4 135 1922 ± 464 28.1 ± 15.0
Cause of death 0.77
 Heart disease 464 2706 ± 311 426 2049 ± 453 24.3 ± 14.6 401 1933 ± 496 28.8 ± 15.8
 Cancer 398 2638 ± 275 359 2038 ± 457 22.4 ± 15.7 356 1925 ± 498 27.2 ± 17.1
 Respiratory disease 143 2710 ± 287 130 2010 ± 466 25.8 ± 14.9 119 1886 ± 512 31.1 ± 16.6
 CVA 102 2652 ± 263 97 1999 ± 478 25.0 ± 14.7 91 1877 ± 521 29.6 ± 16.6
 Trauma 36 2650 ± 262 31 1931 ± 407 26.5 ± 16.5 30 1908 ± 453 27.5 ± 15.0
 Other 131 2657 ± 262 121 2102 ± 465 20.7 ± 15.8 106 1983 ± 477 24.9 ± 15.9
Death to preservation time2 0.27
 <7 hours 195 2639 ± 264 181 2011 ± 471 23.6 ± 15.7 162 1896 ± 524 28.6 ± 18.0
 7–<10 hours 329 2646 ± 280 297 2033 ± 473 23.2 ± 15.4 289 1932 ± 484 27.1 ± 15.7
 10–<14 hours 312 2696 ± 290 280 2034 ± 457 24.2 ± 15.8 273 1908 ± 509 29.2 ± 17.1
 ≥14 hours 438 2696 ± 302 406 2061 ± 443 23.5 ± 14.5 379 1944 ± 487 28.1 ± 15.8
Death to surgery time2 0.33
 <7 days 693 2697 ± 287 633 2080 ± 470 22.8 ± 15.5 605 1971 ± 501 27.2 ± 16.5
 ≥7 days 581 2647 ± 289 531 1991 ± 439 24.6 ± 14.9 498 1869 ± 487 29.4 ± 16.3
1.

P-value is testing for ECD at 1 year vs. screening, not ECL. Model adjusts for pre-operative ECD, donor diabetes status, and recipient diagnosis as fixed effects and surgeon as a random effect, and accounts for the correlations from recipients and donors having both eyes in the study. No adjustment for multiple comparisons has been made. Following the analysis of the CPTS study, the threshold for statistical significance is α=0.01.

2.

Variable was treated as continuous in the model. It has been categorized for display purposes only.

3.

Excludes 206 tissues with either race or ethnicity unknown.

4.

Other races or ethnicities include: Black/African American (n=83), American Indian/Alaskan Native (n=5), Asian (n=4), Native Hawaiian/other Pacific Islander (n=1)—all non-Hispanic, and White Hispanic (n=15).

5.

Pre-operative CIARC–measured ECD used when available. For n=2 tissues, the post-operative CIARC–measured ECD was used. For n=51 tissues, the eye bank–measured cell density was used. CIARC, Cornea Image Analysis Reading Center.

Table 4.

Operative Factors Affecting ECD at 1 Year

Screening 1 Month 1 Year
Risk Factor N ECD
Mean ± SD
N ECD
Mean ± SD
% ECL
Mean ± SD
N ECD
Mean ± SD
% ECL
Mean ± SD
P-Value1
Overall 1274 2674 ± 289 1164 2039 ± 458 23.6 ± 15.2 1103 1925 ± 497 28.2 ± 16.4
Gas used 0.67
 Air 230 2644 ± 281 213 2169 ± 489 18.1 ± 16.0 199 2113 ± 516 20.3 ± 16.8
 Gas 1044 2681 ± 290 951 2011 ± 446 24.9 ± 14.8 904 1883 ± 483 29.9 ± 15.8
% AC filled with gas (N=683)2,3 0.95
 <60% 49 2647 ± 269 43 2047 ± 490 22.2 ± 17.0 44 1912 ± 510 27.8 ± 18.1
 60% to 75% 302 2641 ± 288 275 2011 ± 431 23.5 ± 14.5 267 1884 ± 472 29.0 ± 15.7
 >75% 332 2697 ± 274 296 2001 ± 476 25.7 ± 16.0 267 1919 ± 517 29.1 ± 17.4
Complete air/gas fill duration2 0.97
 0 minutes 535 2676 ± 295 491 2051 ± 481 23.3 ± 15.9 435 1979 ± 518 26.1 ± 17.4
 1 to 10 minutes 710 2676 ± 283 649 2037 ± 438 23.7 ± 14.7 649 1896 ± 476 29.3 ± 15.5
 11 to 60 minutes 29 2612 ± 318 24 1853 ± 491 29.1 ± 15.1 19 1677 ± 593 38.4 ± 18.6
Use of AC maintainer 0.97
 No 1054 2680 ± 291 956 2009 ± 443 24.9 ± 14.8 921 1876 ± 482 30.1 ± 15.9
 Yes 220 2645 ± 275 208 2180 ± 499 17.7 ± 15.9 182 2172 ± 498 18.3 ± 15.8
Was viscoelastic used in AC? 0.72
 No 107 2650 ± 293 94 2178 ± 453 17.8 ± 13.7 88 2146 ± 478 19.4 ± 14.8
 Yes 1167 2677 ± 288 1070 2027 ± 457 24.1 ± 15.2 1015 1906 ± 494 28.9 ± 16.3
Lens surgery 0.05
 No 725 2672 ± 299 659 1994 ± 476 25.3 ± 16.0 621 1877 ± 520 29.9 ± 17.3
 Yes 549 2677 ± 276 505 2098 ± 427 21.5 ± 13.9 482 1986 ± 460 25.9 ± 15.0
Was a resident or fellow involved in preparation of the donor? 0.36
 No 1134 2681 ± 285 1034 2042 ± 441 23.6 ± 14.7 985 1920 ± 488 28.5 ± 16.1
 Yes 140 2622 ± 316 130 2017 ± 578 23.6 ± 19.0 118 1968 ± 569 25.4 ± 18.7
Was a resident or fellow involved in preparation of the recipient? 0.69
 No 1055 2673 ± 286 958 2035 ± 440 23.7 ± 14.7 917 1913 ± 489 28.5 ± 16.3
 Yes 219 2682 ± 302 206 2062 ± 537 23.3 ± 17.6 186 1982 ± 534 26.7 ± 17.1
Was a resident or fellow involved in insertion and positioning of donor? 0.46
 No 1020 2669 ± 287 931 2043 ± 446 23.3 ± 14.8 888 1922 ± 493 28.1 ± 16.3
 Yes 254 2696 ± 296 233 2024 ± 506 24.9 ± 16.8 215 1936 ± 515 28.6 ± 17.1
Insertion method (N=1060)4 0.11
 Straiko modified Jones tube 769 2687 ± 284 703 2013 ± 445 25.0 ± 14.9 702 1876 ± 479 30.2 ± 15.7
 LEITR modified Jones tube 162 2671 ± 328 153 2008 ± 406 24.5 ± 13.3 142 1870 ± 480 29.7 ± 16.3
 Other5 129 2652 ± 278 112 1905 ± 552 27.7 ± 18.9 83 1847 ± 577 31.6 ± 19.2
Incision location 0.08
 Temporal 1192 2673 ± 289 1091 2045 ± 457 23.4 ± 15.1 1033 1931 ± 497 27.9 ± 16.3
 Other6 82 2693 ± 281 73 1950 ± 466 26.7 ± 17.1 70 1836 ± 495 31.8 ± 17.7
Incision site 0.78
 Cornea 1178 2677 ± 288 1077 2024 ± 456 24.2 ± 15.2 1022 1902 ± 494 29.1 ± 16.3
 Scleral tunnel 96 2646 ± 295 87 2225 ± 452 16.0 ± 12.9 81 2215 ± 448 16.8 ± 12.8
Incision size (mm) 0.05
 2.0 ± 0.2 158 2656 ± 321 145 2088 ± 475 21.4 ± 14.5 138 1996 ± 534 25.0 ± 17.3
 2.5 ± 0.2 668 2679 ± 290 607 1974 ± 467 26.2 ± 15.8 553 1848 ± 490 31.1 ± 16.3
 3.0 or greater 448 2675 ± 275 412 2119 ± 424 20.6 ± 13.9 412 2004 ± 479 25.3 ± 15.5
Donor tissue unscroll time (N=1219)2,7 0.002
 ≤2 minutes 641 2681 ± 291 587 2103 ± 426 21.4 ± 13.5 554 1967 ± 486 26.7 ± 15.6
 3 to 5 minutes 435 2660 ± 288 397 1962 ± 476 26.1 ± 16.7 372 1859 ± 494 30.3 ± 17.0
 >5 minutes 143 2680 ± 287 134 1965 ± 509 26.9 ± 16.4 125 1892 ± 524 30.0 ± 16.6
Graft diameter2 0.12
 7.0 to <8.0 mm 733 2684 ± 295 680 2057 ± 421 23.2 ± 13.7 658 1919 ± 469 28.6 ± 15.2
 8.0 to 8.5 mm 541 2661 ± 280 484 2014 ± 506 24.2 ± 17.1 445 1933 ± 537 27.6 ± 18.0
Use of intracameral lidocaine 0.46
 No 730 2690 ± 297 660 2040 ± 430 24.0 ± 14.2 658 1897 ± 481 29.5 ± 15.7
 Yes 544 2654 ± 276 504 2039 ± 493 23.2 ± 16.5 445 1966 ± 517 26.3 ± 17.3
Use of intracameral antimicrobial 0.93
 No 1232 2674 ± 290 1125 2047 ± 460 23.3 ± 15.2 1069 1931 ± 498 28.0 ± 16.4
 Yes 42 2696 ± 265 39 1821 ± 363 32.1 ± 13.0 34 1731 ± 417 35.1 ± 15.1
Use of intracameral steroid NA8
 No 1273 2674 ± 289 1163 2039 ± 458 23.6 ± 15.2 1102 1924 ± 497 28.2 ± 16.4
 Yes 1 3047 ± NA 1 2520 ± NA 17.3 ± NA 1 2447 ± NA 19.7 ± NA
Was pupil constricted using miotic in AC? 0.17
 No 289 2679 ± 290 252 2006 ± 469 24.9 ± 15.6 228 1919 ± 517 28.4 ± 17.6
 Yes 985 2673 ± 289 912 2049 ± 455 23.3 ± 15.1 875 1926 ± 492 28.1 ± 16.1
Any operative complications?9 <0.001
 No 1208 2677 ± 289 1105 2056 ± 444 23.1 ± 14.6 1046 1946 ± 482 27.4 ± 15.8
 Yes 66 2629 ± 290 59 1733 ± 595 34.1 ± 21.7 57 1537 ± 603 41.9 ± 21.1
1.

P-value is testing for ECD at 1 year vs. screening, not ECL. Model adjusts for pre-operative ECD, donor diabetes status, and recipient diagnosis as fixed effects and surgeon as a random effect, and accounts for the correlations from recipients and donors having both eyes in the study. No adjustment for multiple comparisons has been made. Following the analysis of the CPTS study, the threshold for statistical significance is α=0.01.

2.

Variable was treated as continuous in the model. It has been categorized for display purposes only.

3.

Excludes 591 tissues for which the percentage of the anterior chamber filled with gas was not assessed.

4.

Excludes 214 tissues prepared by the surgeon. All of these tissues were inserted with an IOL insertor.

5.

Other insertion methods include: Gueder tube (n=37), Stephen cannula (n=35), Descepro pull-through (n=25), DORC tube (n=12), Tan DMEK Endoglide (n=6), Gunther Weiss glass cannulas (n=6), 2.4mm micro Jones tube (n=5), Jones tube (n=2), older model Straiko modified Jones tube (n=1).

6.

Other incision locations include: Superotemporal (n=42), Inferotemporal (n=35), Superonasal (n=3), Nasal (n=1), Superior (n=1).

7.

Excludes 55 tissues with unknown scroll time.

8.

P-value was not calculated because n=1 in one of the groups.

9.

Operative complications are: difficult unfolding and positioning without use of positioning hook, difficult unfolding and positioning with use of positioning hook, difficult air/gas fill and retention in positioning, reinsertion of donor after partial extrusion, reinsertion of donor after complete extrusion, inverted donor tissue, significant fibrin in anterior chamber, significant hyphemia, vitreous loss, other write-ins.

Table 5.

Results of Multivariate Model Containing Results from the Previous Tables Significant at α=0.01

Effect Adjusted Difference from Reference Group in ECD at 12 Months (99% CI) P-Value1
Pre-Operative CIARC-measured ECD2,3 <0.001
 <2500 0 Reference
 2500–<2750 216 (138, 294)
 2750–<3000 415 (329, 500)
 ≥3000 554 (452, 656)
Eye bank–reported % cell damage by trypan blue staining <0.001
 Little to none (<5%) 0 Reference
 Mild (5–10%) −73 (−143, −3)
 Moderate/severe (10–20%) −161 (−281, −40)
Donor tissue unscroll time2 0.43
 ≤2 minutes 0 Reference
 3 to 5 minutes −58 (−133, 17)
 >5 minutes −15 (−131, 101)
Any operative complications <0.001
 No 0 Reference
 Yes −308 (−450, −166)
Indication for DMEK 0.001
 FECD 0 Reference
 Other −191 (−346, −36)
1.

The model adjusts for surgeon as a random effect and accounts for the correlations from recipients and donors having both eyes in the study. It was fit using n=1005 eye bank–prepared tissues that were not missing any covariate data. Threshold for statistical significance is α=0.01

2.

Variable was treated as continuous in the model. It has been categorized for display purposes only.

3.

Pre-operative CIARC–measured ECD used when available. For n=2 tissues, the post-operative CIARC–measured ECD was used. For n=41 tissues, the eye bank–measured cell density was used. CIARC, Cornea Image Analysis Reading Center.

Mean ECL at 1 year ranged from 26% to 30% across preoperative categorical ECD groups (Table 1). Mean ECL at 1 year was 36% when there was 10–20% endothelial cell damage after lenticule preparation (Table 2), 29% when there was <5% endothelial cell damage after lenticule preparation (Table 2), 40% when the preoperative indication was not FECD (Table 3), 28% when the preoperative indication was FECD (Table 3), 42% when intraoperative complications occurred (Table 4), and 27% when intraoperative complications did not occur (Table 4).

Table 2.

Donor Lenticule Preparation Parameters Affecting ECD at 1 Year

Screening 1 Month 1 Year
Risk Factor N ECD
Mean ± SD
N ECD
Mean ± SD
% ECL
Mean ± SD
N ECD
Mean ± SD
% ECL
Mean ± SD
P-Value1
Overall 1274 2674 ± 289 1164 2039 ± 458 23.6 ± 15.2 1103 1925 ± 497 28.2 ± 16.4
Prepared by 0.04
 Eye bank or combination of eye bank and surgeon 1060 2680 ± 290 968 2000 ± 453 25.2 ± 15.2 927 1873 ± 488 30.3 ± 16.1
 Surgeon 214 2647 ± 280 196 2234 ± 433 15.6 ± 12.7 176 2200 ± 451 17.1 ± 13.6
Timing of tissue preparation (N=1060)2 0.09
 Day of Surgery 2 2460 ± 149 2 1629 ± 320 34.1 ± 9.0 2 1648 ± 188 33.1 ± 3.6
 1 day before surgery 704 2680 ± 289 644 2027 ± 446 24.2 ± 14.7 614 1886 ± 485 29.8 ± 15.9
 2 days before surgery 339 2688 ± 293 308 1946 ± 467 27.5 ± 16.0 301 1844 ± 499 31.5 ± 16.6
 3 days before surgery 15 2535 ± 263 14 1992 ± 404 20.9 ± 11.8 10 1966 ± 367 24.0 ± 10.2
 Separation method (N=1059)2,3 0.21
 Submerged peeling 821 2680 ± 292 754 1983 ± 450 25.9 ± 15.1 716 1847 ± 487 31.2 ± 16.1
 Non-submerged peeling 238 2682 ± 286 214 2062 ± 459 22.8 ± 15.2 210 1961 ± 485 27.1 ± 15.6
Original storage solution 0.04
 Optisol GS 996 2674 ± 294 909 2031 ± 468 24.0 ± 15.4 852 1915 ± 506 28.5 ± 16.7
 Eusol C 164 2677 ± 272 145 2082 ± 400 21.3 ± 14.1 147 1995 ± 433 25.6 ± 14.4
 Kerasave 66 2738 ± 267 64 2111 ± 418 23.1 ± 13.9 61 1967 ± 475 28.5 ± 14.8
 Life 4°C 48 2591 ± 251 46 1976 ± 494 24.0 ± 16.4 43 1820 ± 538 29.9 ± 18.2
Change in storage solution (N=1060)2 0.61
 Original 378 2734 ± 286 356 2029 ± 464 25.6 ± 15.4 340 1917 ± 469 30.0 ± 14.6
 Fresh 682 2650 ± 289 612 1983 ± 446 25.0 ± 15.1 587 1847 ± 497 30.4 ± 16.9
Antifungal added after preparation? (N=682)2,4 0.96
 No 661 2653 ± 287 595 1990 ± 444 24.8 ± 15.0 578 1853 ± 494 30.2 ± 16.8
 Yes 21 2570 ± 328 17 1748 ± 477 33.1 ± 15.3 9 1463 ± 589 44.6 ± 19.8
Tissue preloaded? (N=1060)2 0.23
 No 297 2692 ± 291 276 1933 ± 508 28.4 ± 17.0 275 1832 ± 503 32.2 ± 16.1
 Yes 763 2676 ± 290 692 2027 ± 427 24.0 ± 14.2 652 1889 ± 481 29.5 ± 16.0
Eye bank–reported separation difficulty: tears (N=1060)2 0.75
 None 883 2682 ± 288 807 2005 ± 444 25.1 ± 14.8 774 1874 ± 480 30.2 ± 15.9
 Few/moderate 177 2669 ± 302 161 1976 ± 499 25.8 ± 17.2 153 1867 ± 530 30.6 ± 17.2
Eye bank–reported separation difficulty: adhesions (N=1060)2 0.47
 None 714 2681 ± 299 653 2000 ± 439 25.3 ± 14.5 619 1867 ± 485 30.5 ± 15.9
 Mild 276 2673 ± 263 253 2020 ± 471 24.3 ± 16.2 245 1888 ± 485 29.6 ± 16.5
 Moderate/Severe 70 2697 ± 310 62 1919 ± 526 28.7 ± 17.5 63 1869 ± 535 30.9 ± 17.0
Eye bank–reported % cell damage by trypan blue staining (N=1060)2 <0.001
 Little to none (<5%) 611 2691 ± 290 559 2043 ± 443 23.9 ± 14.7 534 1911 ± 485 29.0 ± 15.9
 Mild (5–10%) 364 2666 ± 291 336 1964 ± 452 26.2 ± 15.2 317 1846 ± 485 31.1 ± 15.9
 Moderate/severe (10–20%) 85 2665 ± 287 73 1841 ± 495 31.3 ± 16.9 76 1712 ± 492 36.1 ± 16.7
Any eye bank observations? (N=1060)2,5 0.02
 No 914 2679 ± 290 840 2016 ± 447 24.6 ± 14.9 794 1885 ± 482 29.8 ± 15.9
 Yes 146 2685 ± 296 128 1898 ± 481 29.2 ± 16.3 133 1797 ± 519 33.2 ± 17.0
1.

P-value is testing for ECD at 1 year vs. screening, not ECL. Model adjusts for pre-operative ECD, donor diabetes status, and recipient diagnosis as fixed effects and surgeon as a random effect, and accounts for the correlations from recipients and donors having both eyes in the study. No adjustment for multiple comparisons has been made. Following the analysis of the CPTS study, the threshold for statistical significance is α=0.01.

2.

Excludes 214 tissues prepared by the surgeon.

3.

Excludes 1 tissue prepared by hydrodissection.

4.

Excludes 378 tissues that were not transferred into a fresh storage solution.

5.

Eye bank observations are defined as the observation of tears, adhesions, or cell damage at or above the “moderate” level.

Table 3.

Recipient Factors Affecting ECD at 1 Year

Screening 1 Month 1 Year
Risk Factor N ECD
Mean ± SD
N ECD
Mean ± SD
% ECL
Mean ± SD
N ECD
Mean ± SD
% ECL
Mean ± SD
P-Value1
Overall 1274 2674 ± 289 1164 2039 ± 458 23.6 ± 15.2 1103 1925 ± 497 28.2 ± 16.4
Age2 0.26
 39 to 70 672 2671 ± 288 619 2037 ± 467 23.7 ± 15.5 583 1917 ± 505 28.4 ± 16.8
 71 to 90 602 2678 ± 290 545 2042 ± 448 23.6 ± 14.9 520 1934 ± 489 27.9 ± 16.0
Sex 0.83
 Female 724 2683 ± 299 664 2045 ± 464 23.8 ± 15.3 626 1917 ± 496 28.6 ± 16.3
 Male 550 2663 ± 274 500 2032 ± 451 23.4 ± 15.2 477 1936 ± 499 27.6 ± 16.6
Race/ethnicity 0.07
 Non-Hispanic White 1215 2674 ± 289 1109 2049 ± 451 23.2 ± 14.9 1052 1932 ± 493 27.9 ± 16.2
 Other3 59 2694 ± 277 55 1853 ± 556 31.3 ± 19.1 51 1782 ± 558 34.1 ± 19.4
Diabetes4 0.35
 Without diabetes 982 2679 ± 291 903 2040 ± 468 23.7 ± 15.5 863 1929 ± 502 28.2 ± 16.6
 With diabetes 292 2658 ± 280 261 2037 ± 425 23.2 ± 14.1 240 1910 ± 480 28.3 ± 15.8
Indication for DMEK <0.001
 FECD 1229 2671 ± 290 1124 2044 ± 458 23.4 ± 15.1 1068 1934 ± 492 27.8 ± 16.1
 Other5 45 2760 ± 229 40 1922 ± 461 30.2 ± 16.6 35 1643 ± 579 40.2 ± 20.9
Pre-operative lens status 0.17
 Phakic 705 2667 ± 285 643 2066 ± 443 22.4 ± 14.5 615 1947 ± 477 27.2 ± 15.7
 Pseudophakic 569 2683 ± 294 521 2007 ± 475 25.1 ± 16.0 488 1897 ± 520 29.4 ± 17.2
Pre-operative/post-operative lens status (N=1229)6 0.16
 Phakic/Phakic 154 2633 ± 315 136 1947 ± 480 26.0 ± 15.9 131 1807 ± 515 31.8 ± 17.5
 Phakic/Pseudophakic 549 2677 ± 276 505 2098 ± 427 21.5 ± 13.9 482 1986 ± 460 25.9 ± 15.0
 Pseudophakic/Pseudophakic 526 2676 ± 297 483 2014 ± 476 24.7 ± 15.9 455 1915 ± 511 28.6 ± 16.6
Presence of pre-operative focal epithelial edema (N=1229)6 0.99
 No 992 2674 ± 291 906 2071 ± 454 22.5 ± 14.7 864 1956 ± 489 27.0 ± 15.9
 Yes 237 2660 ± 289 218 1932 ± 458 27.1 ± 16.2 204 1839 ± 492 31.0 ± 16.8
Evidence of corneal abnormality other than primary diagnosis7 0.46
 No 1113 2676 ± 289 1017 2045 ± 449 23.5 ± 14.9 955 1930 ± 490 28.0 ± 16.2
 Yes 161 2666 ± 285 147 2003 ± 520 24.8 ± 17.2 148 1892 ± 542 29.2 ± 18.0
Baseline IOP2 0.89
 <20 1203 2675 ± 291 1100 2045 ± 458 23.4 ± 15.2 1040 1929 ± 500 28.0 ± 16.5
 ≥20 71 2672 ± 246 64 1951 ± 451 26.9 ± 15.6 63 1857 ± 446 30.8 ± 14.9
Glaucoma medications at enrollment 0.16
 No 1203 2672 ± 291 1098 2042 ± 458 23.5 ± 15.2 1046 1931 ± 494 27.9 ± 16.3
 Yes 71 2711 ± 253 66 1997 ± 462 26.4 ± 15.5 57 1806 ± 542 32.6 ± 18.6
Previous glaucoma surgery 0.58
 No 1246 2673 ± 289 1136 2042 ± 458 23.5 ± 15.2 1080 1928 ± 497 28.1 ± 16.3
 Yes 28 2745 ± 283 28 1932 ± 457 29.1 ± 16.7 23 1761 ± 505 34.3 ± 19.3
Previous glaucoma surgery or medications 0.32
 No 1192 2672 ± 291 1087 2043 ± 458 23.4 ± 15.2 1036 1932 ± 496 27.9 ± 16.3
 Yes 82 2708 ± 260 77 1990 ± 459 26.5 ± 15.4 67 1819 ± 513 31.9 ± 17.8
Current smoker 0.04
 No 1217 2669 ± 287 1110 2037 ± 454 23.6 ± 15.1 1059 1926 ± 492 28.0 ± 16.2
 Yes 57 2781 ± 309 54 2092 ± 549 25.1 ± 17.3 44 1898 ± 607 31.5 ± 20.4
1.

P-value is testing for ECD at 1 year vs. screening, not ECL. Model adjusts for pre-operative ECD, donor diabetes status, and recipient diagnosis as fixed effects and surgeon as a random effect, and accounts for the correlations from recipients and donors having both eyes in the study. No adjustment for multiple comparisons has been made. Following the analysis of the CPTS study, the threshold for statistical significance is α=0.01.

2.

Variable was treated as continuous in the model. It has been categorized for display purposes only.

3.

Other races or ethnicities include: Black/African American (n=33), American Indian/Alaskan Native (n=2), Asian (n=2), Native Hawaiian/other Pacific Islander (n=1), more than one race (n=5)—all non-Hispanic, White Hispanic (n=14), and Black/African American Hispanic (n=2).

4.

Recipients with diabetes include those with a history of diabetes at baseline, or HbA1c at baseline ≥6.5.

5.

Other diagnoses: Failed DMEK (n=9), Failed DSAEK (n=16), PBK (n=20).

6.

Excludes 45 tissues without an FECD diagnosis.

7.

Corneal abnormalities include: map-dot-fingerprint, subepithelial scarring, stromal scarring, LASIK, keratoconus, Salzmann nodule, band keratopathy, PBK.

Discussion

The DEKS found that diabetes in the donor did not affect graft survival or ECL at 1 year after DMEK, and that ECL from preoperative was approximately 28% for all eyes with analyzable endothelial images.7,8 In this pre-defined secondary DEKS analysis, ECD at 1 year after DMEK was associated with preoperative donor ECD, endothelial cell damage after lenticule preparation, recipient diagnosis, and operative complications.

Donor Factors

Lower donor preoperative ECD was associated with lower ECD at 1 year after DMEK, similar to after DSAEK in the CPTS,2 though there was little variation in ECL from preoperative at 1 year (26–30%) across categorical groups of preoperative ECD (<2500, 2500 to <2750, 2750 to <3000, ≥3000 cells/mm2; Table 1). In the parallel DEKS secondary analysis examining risk factors for graft success, preoperative donor ECD was not associated with graft survival at 1 year.9 The Cornea Donor Study (CDS) and the CPTS found that graft survival after PK and DSAEK, respectively, was not associated with preoperative ECD but was associated with postoperative ECD at 6 months,1,14 indicating that early ECL is more important than preoperative ECD (when >2300 cells/mm2). In fact, the highest ECL after endothelial keratoplasty, including in the DEKS, occurs by 1 month after surgery,8,15 and this is probably explained by endothelial cell damage during donor lenticule preparation and surgical manipulation.

The DEKS also assessed the viability of the donor endothelium at the end of lenticule preparation by visually assessing the percentage of endothelial cell damage using trypan blue staining.6,13 In contrast to specular or confocal microscopy images that typically represent <0.5% of the total endothelial surface area, staining donor corneas with trypan blue assesses the entire donor endothelial area. Donor tissue with 10–20% endothelial cell damage was associated with higher ECL at 1 year after DMEK (36%) compared to donor tissue with <5% damage (29%). Donor tissues with >20% endothelial cell damage by this method were excluded from the DEKS. Because donor preoperative ECD and donor cell damage by trypan blue staining were independent risk factors for lower ECD at 1 year after DMEK in the multivariable model (Table 5), the DEKS has shown that estimating endothelial cell damage by trypan blue staining is an important complementary assessment to measuring donor ECD. Cutoff criteria for both parameters are therefore important when selecting suitable donor tissue for keratoplasty, and data for both should also be provided to surgeons when accepting donor tissue. Automating the analysis of trypan blue staining of donor lenticules16 would help promote standardization and efficiency for eye banks. In fact, the DEKS Area of Cell Damage (ACD) ancillary study will investigate objective and automated methods of quantifying cell damage in a subset of eyes enrolled in the DEKS (personal communication with Dr. J, Hou, Gift of Sight, Minneapolis, MN, on July 11, 2026).16

Donor factors not associated with higher ECL at 1 year after DMEK included donor age, donor sex, cause of death, death to preservation time, and death to surgery time. Donor age was associated with higher ECL at 5 and 10 years after PK in the CDS3,4 but not at 3 years after DSAEK in the CPTS.2 While female donors were associated with lower ECL at 5 years after PK,4 the same relationship was not present after endothelial keratoplasty in the DEKS or the CPTS.2 Donor tissue preparation factors not associated with higher ECL included the timing of lenticule preparation relative to surgery,17 separation method or difficulty, storage solution,18 and whether the tissue was preloaded or not. There was a trend (Table 2) towards higher ECL when the eye bank made tissue observations (of tears, adhesions, endothelial cell damage, etc.), but this became non-significant in the final statistical model. Of note, while ECL appeared to be lower for surgeon-prepared tissue (17%) vs. eye bank and combined eye bank/surgeon preparation (30%), the difference was not statistically significant (statistical models were adjusted for surgeon effect because outcomes from the same surgeon were correlated, i.e. they were not independent data; only 3 surgeons at 2 sites prepared their own tissue).

Recipient Factors

A recipient diagnosis other than FECD was associated with higher ECL (40% vs. 28%) at 1 year after DMEK. While only 45 eyes (<4%) in this analysis (and the overall DEKS cohort) had a recipient diagnosis of pseudophakic corneal edema or previous failed endothelial keratoplasty, the findings are consistent with other series after DMEK19–21 and with the CPTS, which found higher ECL at 3 years after DSAEK for eyes with pseudophakic/aphakic corneal edema compared to FECD.2 Lower ECL in the setting of FECD might be explained by the healthy peripheral endothelial cell reserve in FECD, which migrate centrally after Descemet stripping only procedures resulting in resolution of corneal edema.22,23 Healthier peripheral endothelial cells in FECD might help to slow ECL after DMEK compared to indications other than FECD in which peripheral endothelial cells are depleted or dysfunctional. Of note, while operative complications were also more frequent in eyes without FECD (13%) compared to eyes with FECD (5%, P=0.007), recipient diagnosis and operative complications were independent risk factors for ECL in the final statistical model. Although the parallel DEKS analysis did not find an association between recipient diagnosis and graft survival at 1 year after DMEK,9 longer follow-up is required study to better assess this relationship. Indeed, with longer follow-up in the CPTS and CDS, recipient diagnosis was associated with graft failure after DSAEK and PK, respectively.24,25

Recipient factors not associated with higher ECL included preoperative and postoperative lens status, baseline intraocular pressure, use of glaucoma medications, or previous glaucoma surgery. Only 28 eyes had had previous glaucoma surgery, all of which were either laser trabeculoplasty or minimally invasive glaucoma surgery (MIGS), and the DEKS excluded eyes with a glaucoma drainage device, which has been associated with higher ECL and graft failure after endothelial keratoplasty.26–28

Operative factors

The occurrence of an intraoperative complication, as reported by the surgeon, was the only operative risk factor associated with higher ECL at 1 year after DMEK, and was the only risk factor for graft failure in the parallel 1-year graft success study.9 Operative complications included complications from concomitant surgery (e.g. posterior capsule rupture or vitreous loss with combined cataract surgery) and donor tissue manipulation (including difficult positioning, extrusion, and inversion). In other series, higher ECL has been associated with difficulty unfolding the DMEK graft29,30 and with longer operative time.31 In the DEKS, when intraoperative complications were removed from the final multivariable model, the time taken to unscroll the DMEK graft (defined as from the start of tissue unscrolling to injection of the air/gas tamponade) became a significant risk factor for higher ECL, indicating its strong correlation with intraoperative complications. In the CPTS, operative complications were also associated with higher ECL and graft failure after DSAEK,2,24 and were an independent risk factor (in addition to ECL) for late endothelial graft failure.1 The findings reflect the additional donor tissue surgical manipulation associated with endothelial keratoplasty compared to PK. Because the DEKS excluded high-risk eyes (e.g. with previous failed PK or glaucoma drainage devices) that may be associated with increased difficulty unfolding the DMEK graft, higher ECL is expected in these eyes compared to that found in the DEKS.27

Operative factors not associated with higher ECL included the percentage of anterior chamber air/gas fill, complete air/gas fill duration, combined lens surgery, insertion method and location, incision site and size, graft diameter, trainee participation in donor or recipient preparation, and trainee participation in graft insertion and positioning. Although ECL appeared lower when using air (20%) compared to gas (30%), the difference was not significant after adjusting for surgeon effect (79% of the 230 cases that used air were by 2 surgeons at 1 clinical site who also prepared their own tissue), consistent with a meta-analysis that found no difference in ECL between air and 20% sulfur hexafluoride.32

Strengths and Limitations

This analysis has several strengths, including the large sample size with prospective follow-up, and rigorous, standardized endothelial image analysis methods. Associated donor and recipient data were collected in a standardized manner enabling assessment of multiple candidate factors associated with ECL. With only three failed grafts at 1 year that were not primary or early failures,7 the potential for bias in the endothelial cell analysis due to attrition was minimal. Similarly, while unanalyzable postoperative images might have been associated with lower postoperative ECD, any bias introduced would have been minimal with only 60 eyes and 12 eyes having unanalyzable images at 1 month and 12 months, respectively. Although the visual assessment of endothelial cell damage from trypan blue staining was subjective, all observers were trained and examined on their interpretations to promote standardization and ensure accuracy within 5%. While subjective, this assessment, which is currently used by eye banks in clinical settings to determine tissue suitability, was shown to be important and warrants the development of automated analyses to eliminate subjectivity.16 The results of this study are applicable to most DMEK cases that use intermediate-term cold storage of donor tissue, but because the DEKS excluded higher-risk eyes, including those with failed PK, glaucoma drainage devices, and uveitis, the results will not apply to more complex cases of DMEK. Finally, the current analysis did not investigate postoperative factors, such as the need for secondary procedures for graft dislocation, that may also affect ECL (postoperative events will be reported separately).33,34

Conclusions

The modifiable risk factors for higher ECL at 1 year after DMEK were intraoperative complications and donor endothelial cell damage after lenticule preparation. Operative complications were also a risk factor for graft failure at 1 year after DMEK,9 indicating the importance of minimizing them for improved longer-term graft survival. Comparing longer-term ECL in the setting of operative complications between DMEK and DSAEK will be interesting as this might help guide case selection for each procedure. Such ECL data at 3 and 5 years will become available in the National Eye Institute-funded extension to the DEKS, which will include a subset of the DEKS cohort.35 Donor endothelial cell damage after lenticule preparation emerged as an important risk factor for higher ECL in the DEKS, and it presents an opportunity for eye banks to benchmark their lenticule preparation outcomes in the context of clinical outcomes. While donor endothelial cell damage did not emerge as a risk factor for graft failure at 1 year,9 extended follow-up in the DEKS will determine its association with longer-term graft failure.35

Funding/Support:

This work was supported by cooperative agreements with the National Eye Institute, National Institutes of Health, Department of Health and Human Services (EY030030 and EY030039). Sponsors: Eye Bank Association of America, The Cornea Society, Cleveland Eye Bank Foundation, Beauty of Sight (formerly Florida Lions Eye Bank), CorneaGen, Eversight, Eye Bank for Sight Restoration, Eye Bank of Kentucky, Gift of Sight, Iowa Lions Eye Bank, Kenneth Maverick MD, Lions Eye Bank of Wisconsin, San Antonio Eye Bank, San Diego Eye Bank, Utah Lions Eye Bank, VisionFirst, and VisionGift.

Abbreviations:

CDS

Cornea Donor Study

CI

confidence interval

CPTS

Cornea Preservation Time Study

DEKS

Diabetes Endothelial Keratoplasty Study

DMEK

Descemet membrane endothelial keratoplasty

DSAEK

Descemet stripping automated endothelial keratoplasty

ECD

endothelial cell density

ECL

endothelial cell loss

FECD

Fuchs endothelial cornea dystrophy

PK

penetrating keratoplasty

Diabetes Endothelial Keratoplasty Study Group

Francis W. Price Jr. MD Price Vision Group Indianapolis, IN
Anjulie Gang MD Price Vision Group Indianapolis, IN
David Verdier MD Verdier Eye Center Grand Rapids, MI
Keith H. Baratz MD Mayo Clinic Rochester, MN
Shahzad I. Mian MD University of Michigan Ann Arbor, MI
Christopher Hood MD University of Michigan Ann Arbor, MI
Nambi Nallasamy MD University of Michigan Ann Arbor, MI
Angela Verkade MD University of Michigan Ann Arbor, MI
Sudeep Pramanik MD Mid-Atlantic Cornea Consultants Baltimore, MD
Mark A. Greiner MD University of Iowa Hospials and Clinics Iowa City, IA
Christopher Sales MD University of Iowa Hospials and Clinics Iowa City, IA
Lawrence Tenkman MD Bennett & Bloom Eye Centers Louisville, KY
Christopher Ketcherside MD Kansas City Eye Clinic Overland Park, KS
Evan Schoenberg MD Georgia Eye Partners Atlanta, GA
James Huffman MD Huffman and Huffman PSC Lexington, KY
Paul Phillips MD Sightline Ophthalmic Associates Pittsburgh, PA
Divya Srikumaran MD The Wilmer Eye Institute/Johns Hopkins Baltimore, MD
Yassine Daoud MD The Wilmer Eye Institute/Johns Hopkins Baltimore, MD
Allen Eghrari MD The Wilmer Eye Institute/Johns Hopkins Baltimore, MD
Albert Jun MD PhD The Wilmer Eye Institute/Johns Hopkins Baltimore, MD
Yong Kam MD Moyes Eye Center Kansas City, MO
Mark Terry MD Legacy Devers Eye Institute Portland, OR
Jessica Chen MD Legacy Devers Eye Institute Portland, OR
Michael Straiko MD Legacy Devers Eye Institute Portland, OR
Peter Veldman MD University of Chicago Chicago, IL
Parag Majmudar MD Chicago Cornea Consultants Chicago, IL
Rachel Epstein MD Chicago Cornea Consultants Chicago, IL
Neal Vaidya MD Chicago Cornea Consultants Chicago, IL
Ula Jurkunas MD Massachusetts Eye and Ear Boston, MA
Nandini Venkateswaran MD Massachusetts Eye and Ear Boston, MA
Ari Brandsdorfer MD Consulting Ophthalmologists PC Glastonbury, CT
David Hardten MD Minnesota Eye Consultants Bloomington, MN
Sherman Reeves MD Minnesota Eye Consultants Bloomington, MN
Ellen Koo MD Bascom Palmer Eye Institute Miami, FL
Michael Greenwood MD Vance Thomson Vision West Fargo, ND
Jamie Alexander MD Cornea Associates of Texas Dallas, TX
John Bokosky MD Eye Care of San Diego San Diego, CA

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Trial Registration: NCT05134480, ClinicalTrials.gov

Meeting Presentation: The material within this manuscript has been submitted for presentation at the American Academy of Ophthalmology Annual Meeting, 2026.

Conflict of Interest: None of the authors have relevant conflicting relationships.

References

  • 1.Patel SV, Lass JH, Benetz BA, et al. Postoperative endothelial cell density is associated with late endothelial graft failure after Descemet stripping automated endothelial keratoplasty. Ophthalmology 2019;126(8):1076–83. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Lass JH, Benetz BA, Patel SV, et al. Donor, recipient, and operative factors associated with increased endothelial cell loss in the Cornea Preservation Time Study. JAMA Ophthalmol 2019;137(2):185–93. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Lass JH, Benetz BA, Gal RL, et al. Donor age and factors related to endothelial cell loss 10 years after penetrating keratoplasty: Specular Microscopy Ancillary Study. Ophthalmology 2013;120(12):2428–35. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Lass JH, Beck RW, Benetz BA, et al. Baseline factors related to endothelial cell loss following penetrating keratoplasty. Arch Ophthalmol 2011;129(9):1149–54. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Cornea Donor Study Investigator Group, Lass JH, Gal RL, et al. Donor age and corneal endothelial cell loss 5 years after successful corneal transplantation. Specular Microscopy Ancillary Study results. Ophthalmology 2008;115(4):627–32.e8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Price MO, Szczotka-Flynn LB, Bauza CE, et al. Diabetes Endothelial Keratoplasty Study: Methods and impact on the use of corneas from donors with diabetes for Descemet membrane endothelial keratoplasty. Cornea 2026;45(1):312–21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Price FW Jr., Szczotka-Flynn LB, Price MO, et al. Donor diabetes and 1-year Descemet membrane endothelial keratoplasty success rate: A randomized clinical trial. JAMA Ophthalmol 2025;143(12):1043–51. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Lass JH, Benetz BA, Verdier DD, et al. Endothelial cell loss 1 year after successful DMEK in the Diabetes Endothelial Keratoplasty Study: A randomized clinical trial. JAMA Ophthalmol 2025;143(12):1053–60. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Price MO, Szczotka-Flynn LB, Reed ZW, et al. Factors associated with successful Descemet membrane endothelial keratoplasty in the Diabetes Endothelial Keratoplasty Study. Ophthalmology 2026;In Preparation. [DOI] [PubMed] [Google Scholar]
  • 10.Benetz BA, Gal RL, Ruedy KJ, et al. Specular Microscopy Ancillary Study methods for donor endothelial cell density determination of Cornea Donor Study images. Current Eye Research 2006;31(4):319–27. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Patel SV, McLaren JW, Bachman LA, Bourne WM. Comparison of flex-center, center, and corner methods of corneal endothelial cell analysis. Cornea 2010;29(9):1042–7. [DOI] [PubMed] [Google Scholar]
  • 12.Ohno K, Nelson LR, McLaren JW, et al. Comparison of recording systems and analysis methods in specular microscopy. Cornea 1999;18(4):416–23. [DOI] [PubMed] [Google Scholar]
  • 13.Szkarlat MR, Hicks N, Titus MS, Sawant OB. Corneal endothelium viability assay using trypan blue dye after preloaded Descemet membrane endothelial keratoplasty graft preparation. Cornea 2024;43(6):771–6. [DOI] [PubMed] [Google Scholar]
  • 14.Lass JH, Sugar A, Benetz BA, et al. Endothelial cell density to predict endothelial graft failure after penetrating keratoplasty. Arch Ophthalmol 2010;128(1):63–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Wacker K, Baratz KH, Maguire LJ, et al. Descemet stripping endothelial keratoplasty for Fuchs’ endothelial corneal dystrophy: Five-year results of a prospective study. Ophthalmology 2016;123(1):154–60. [DOI] [PubMed] [Google Scholar]
  • 16.Bedard P, Justin JJ, Hou JH. Trypan-assisted automated endothelial cell loss measurements compared with specular microscopy. Cornea 2021;40(8):1031–5. [DOI] [PubMed] [Google Scholar]
  • 17.Feng MT, Burkhart ZN, Price FW Jr., Price MO. Effect of donor preparation-to-use times on Descemet membrane endothelial keratoplasty outcomes. Cornea 2013;32(8):1080–2. [DOI] [PubMed] [Google Scholar]
  • 18.Price MO, Knight OJ, Benetz BA, et al. Randomized, prospective, single-masked clinical trial of endothelial keratoplasty performance with 2 donor cornea 4°C storage solutions and associated chambers. Cornea 2015;34(3):253–6. [DOI] [PubMed] [Google Scholar]
  • 19.Peraza-Nieves J, Baydoun L, Dapena I, et al. Two-year clinical outcome of 500 consecutive cases undergoing Descemet membrane endothelial keratoplasty. Cornea 2017;36(6):655–60. [DOI] [PubMed] [Google Scholar]
  • 20.Birbal RS, Baydoun L, Ham L, et al. Effect of surgical indication and preoperative lens status on Descemet membrane endothelial keratoplasty outcomes. Am J Ophthalmol 2020;212:79–87. [DOI] [PubMed] [Google Scholar]
  • 21.Baydoun L, Ham L, Borderie V, et al. Endothelial survival after Descemet membrane endothelial keratoplasty: Effect of surgical indication and graft adherence status. JAMA Ophthalmol 2015;133(11):1277–85. [DOI] [PubMed] [Google Scholar]
  • 22.Moloney G, Petsoglou C, Ball M, et al. Descemetorhexis without grafting for Fuchs endothelial dystrophy-supplementation with topical ripasudil. Cornea 2017;36(6):642–8. [DOI] [PubMed] [Google Scholar]
  • 23.Borkar DS, Veldman P, Colby KA. Treatment of Fuchs endothelial dystrophy by Descemet stripping without endothelial keratoplasty. Cornea 2016;35(10):1267–73. [DOI] [PubMed] [Google Scholar]
  • 24.Terry MA, Aldave AJ, Szczotka-Flynn LB, et al. Donor, recipient, and operative factors associated with graft success in the Cornea Preservation Time Study. Ophthalmology 2018;125(11):1700–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Sugar A, Gal RL, Kollman C, et al. Factors associated with corneal graft survival in the Cornea Donor Study. JAMA ophthalmology 2015;133(3):246–54. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Birbal RS, Tong CM, Dapena I, et al. Clinical outcomes of Descemet membrane endothelial keratoplasty in eyes with a glaucoma drainage device. Am J Ophthalmol 2019;199:150–8. [DOI] [PubMed] [Google Scholar]
  • 27.Sorkin N, Mimouni M, Kisilevsky E, et al. Four-year survival of Descemet membrane endothelial keratoplasty in patients with previous glaucoma surgery. Am J Ophthalmol 2020;218:7–16. [DOI] [PubMed] [Google Scholar]
  • 28.Patel SV, Hodge DO, Winkler NS, et al. Graft survival, graft rejection, and glaucoma in a consecutive series of Descemet stripping endothelial keratoplasty. Cornea 2023;42(5):549–56. [DOI] [PubMed] [Google Scholar]
  • 29.Maier AK, Gundlach E, Schroeter J, et al. Influence of the difficulty of graft unfolding and attachment on the outcome in Descemet membrane endothelial keratoplasty. Graefes Arch Clin Exp Ophthalmol 2015;253(6):895–900. [DOI] [PubMed] [Google Scholar]
  • 30.Gundlach E, Spiller N, Pilger D, et al. Impact of difficult unfolding and attachment of the graft lamella on the long-term outcome after Descemet membrane endothelial keratoplasty. Graefes Arch Clin Exp Ophthalmol 2020;258(11):2459–65. [DOI] [PubMed] [Google Scholar]
  • 31.Leterrier J, Mastrangelo L, Goetz C, et al. Preoperative and perioperative factors that predict endothelial cell loss 1 year after uncomplicated Descemet membrane endothelial keratoplasty. PLoS One 2025;20(12):e0339346. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Marques RE, Guerra PS, Sousa DC, et al. Sulfur hexafluoride 20% versus air 100% for anterior chamber tamponade in DMEK: A meta-analysis. Cornea 2018;37(6):691–7. [DOI] [PubMed] [Google Scholar]
  • 33.Dunker S, Winkens B, van den Biggelaar F, et al. Rebubbling and graft failure in Descemet membrane endothelial keratoplasty: A prospective Dutch registry study. Br J Ophthalmol 2023;107(1):17–23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Tapley JL, Hill JR, Bauer AJ, et al. Rate of endothelial cell loss and graft survival in Descemet membrane endothelial keratoplasty in eyes requiring a rebubble. Cornea 2023;42(8):934–9. [DOI] [PubMed] [Google Scholar]
  • 35.Lass JH. Effect of donor diabetes and other factors on corneal transplant endothelial cell loss and success at 5 years (DEKS). 2026, https://clinicaltrials.gov/study/NCT07217249

RESOURCES